14例原发性甲状腺鳞癌的临床分析  

Clinical analysis of 14 cases of primary squamous cell carcinoma of thyroid gland

作　　者：何道金 刘林[2] 张兴霞 张帅 He Daojin;Liu Lin;Zhang Xingxia(General Surgery Department,People's Hospital of Lixia District of Jinan,Jinan 250013,China)

机构地区：[1]济南市历下区人民医院普外科,250013 [2]解放军总医院普通外科医学部甲状腺(疝)外科 [3]山东省立第三医院感染疾病科 [4]淄博市周村区人民医院普外科

出　　处：《中华保健医学杂志》2021年第5期496-498,共3页Chinese Journal of Health Care and Medicine

摘　　要：目的分析原发性甲状腺鳞癌(primary squamous cell carcimoma of thyroid gland,PSCCT)的临床特征及多线治疗对预后的影响。方法回顾性选择2006年1月~2020年12月解放军总医院收治的病理检查确诊为PSCCT的患者14例,收集术前彩超,细针穿刺细胞学检查、彩超引导下穿刺病理检查以及手术方法;按照是否应用多线治疗(化疗、免疫治疗、靶向治疗)分组,进行生存分析。结果14例患者中,有5例采取了多线治疗,9例未采取多线治疗,随访时间45 d至15年。应用多线治疗组预估生存期为2476.66 d,非多线治疗组预估生存期1019.92 d,多线治疗的生存预期要远优于非多线治疗,差异有统计学意义(P<0.05)。结论彩超检查可以进行初筛,细针穿刺和彩超引导下穿刺病理检查有较高的确诊率,多线治疗对于PSCCT有更好的治疗效果。Objective To analyze the clinical features of primary squamous cell carcimoma of thyroid gland(PSCCT)and the effect of multi line therapy on prognosis.Methods From January,2006 to December,2020,14 patients with PSCCT diagnosed by pathological examination in PLA General Hospital were selected.Preoperative color Doppler ultrasound,fine needle aspiration cytology,ultrasound-guided biopsy and surgical methods were collected;The patients were divided into two groups according to whether to use multi line therapy and the survival analysis was performed.Results Of the 14 patients,5 cases were treated with multi line therapy(chemotherapy,immunotherapy and targeted treatment),9 cases did not take multi-line treatment,and the follow-up time was 45 days-15 years.The estimated survival time of multi line therapy group was 2476.66 days,and that of non multi line therapy group was 1019.92 days.The survival expectation of multi line therapy is much better than that of non multi line therapy(P<0.05).Conclusion Color Doppler ultrasound can be used for primary screening,fine needle aspiration and color Doppler ultrasound-guided biopsy have higher diagnostic rate,and multi line therapy has better therapeutic effect for PSCCT.

关 键 词：甲状腺鳞癌 化疗 免疫治疗 靶向治疗 

分 类 号：R736[医药卫生—肿瘤]